Menu
6th CONGRESS OF THE SKIN INFLAMMATION & PSORIASIS INTERNATIONAL NETWORK

SCIENTIFIC PROGRAMME

Draft Preliminary Programme

Thursday, april 25

 

9:30-11:30 - Educational course on psoriasis

 

Chairs: Esteban Dauden (Spain), Luigi Naldi (Italy)

1. Genetics/pathogenesis - Paola di Meglio (UK)

2. Comorbidities - Tiago Torres (Portugal)

3. Topical therapy - Rolland Gyulai (Hungary)

4. Non-biologic systemic therapy - Paola Cardenas (Colombia)

5. Biologic systemic therapy - David Moreno (Spain)

 

11:30-12:30    Satellite Symposia

12.30-14.00    Welcome reception
 
14.00-14:10 – Congress Opening:

Fondation René Touraine Welcome and update on SPIN

 

14:10-16.00 – Plenary 1: Genetics and pathogenesis in psoriasis and atopic dermatitis

 

Chairs: Pedro Herranz (Spain) & Georg Stingl (Austria)

 

1. Genetics in psoriasis and atopic dermatitis - Jonathan Barker (UK)

2. New developments in immunopathogenesis of psoriasis- Speaker TBC

3. Genetics and immunopathogenesis of pustular variants of psoriasis - Hervé Bachelez (France)

4. Autoimmunity vs autoinflammation in psoriasis - Spearker TBC

5. Pathogenesis in psoriasis and atopic dermatitis. Similarities and differences - Emma Guttman-Yassky (US)

 

16.00-16.30 – Break & Discussed E-Posters 

 

16.30-18.00 – Focus Session 1: Epidemiology and registries

 

Chairs: Paula Seijo-Dávila (Spain) & Luigi Naldi (Italy)

 

1. Registries in dermatology: strengths and learning points - Phyllis Spuls (Netherlands)

2. Epidemiology of major inflammatory skin diseases anno 2019 - Luigi Naldi (Italy)

3. Epidemiology of major inflammatory skin diseases in emerging countries - Alur Kumar (India)

4. Comorbidity occurrence in major inflammatory skin diseases - Alexander Egeberg (Denmark)


FREE COMMUNICATIONS:
 

P001

SAFETY EVENTS OCCURRING AMONG PATIENTS EXPOSED TO IXEKIZUMAB IN THE CORRONA PSORIASIS REGISTRY

E.Grace *, B.Zhu , W.Malley , J.O’Brien , R.Magner , N.Agada , G.Gallo , T.Bhutani  (Indianapolis, United States)

 

P002

NUMBER NEEDED TO TREAT AND COST PER RESPONDER FOR FLEXIBLE ADALIMUMAB DOSING IN THE TREATMENT OF PSORIASIS IN PATIENTS WITH SUBOPTIMAL RESPONSE TO 40MG EVERY OTHER WEEK DOSING

L. J.Savage *, V.Garcia-Horton , J.Li , L.Yin , K. A.Betts , B.Calimlim  (Leeds, United Kingdom)

 

P003

RESPONSE TO ADALIMUMAB IN PATIENTS WITH PLAQUE PSORIASIS BY ASSOCIATED MANIFESTATIONS: ANALYSES FROM THE BRITISH ASSOCIATION OF DERMATOLOGISTS BIOLOGICS AND IMMUNOMODULATORS REGISTER

L. J.Savage *, D.Dasgupta , O.Reyes-Servin , B.Calimlim  (Leeds, United Kingdom)

 

  
16.30-18.00 – Focus Session 2: Advances in target-oriented therapy

 

Chairs: Romana Ceovic (Croatia) & Skaidra Valiukeviciene (Lithuania)

 

1. Atopic dermatitis - Spearker TBC

2. Psoriasis - Alexander Nast (Germany)

3. Psoriatic arthritis - Wolf-Henning Boehncke (Switzerland)

4. Biomarkers in psoriasis and atopic dermatitis - Spearker TBC

 

FREE COMMUNICATIONS:
 

P004

GUSELKUMAB DEMONSTRATES SUPERIOR LONG-TERM RESPONSES COMPARED WITH SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE ECLIPSE TRIAL

K.Reich  *, A.Armstrong  , A.Blauvelt  , S.Li  , M.-C.Hsu  , S.Flavin  , B.Randazzo  , R.Langley   (Hamburg, Germany)

 

P005

LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: RESULTS FROM MORE THAN 17000 PATIENT-YEARS OF EXPOSURE

C. E.Griffiths *, M. G.Lebwohl , A.Blauvelt , K.Reich , M.Gooderham , T.Terui , N.Agada , W.Xu , G.Gallo  (Manchester, United Kingdom)

 

P006

IMMEDIATE ONSET OF ACTION OF BRODALUMAB COMPARED WITH USTEKINUMAB: RESULTS FROM THE PHASE 3 AMAGINE-2 AND -3 STUDIES

S.Philipp *, J.Hansen , V.Schultz Nielsen , A.Chiricozzi  (Berlin, Germany)

 


 

Friday, April 26  

 

08.30-10.00 – Focus Session 3: Autoinflammation and autoimmunity

 

Chairs: Lara Ferrandiz (Spain) & Richard Warren (UK)

 

1. Autoimmunity in psoriasis - Jörg Prinz (Germany)

2. Live imaging of cutaneous immune-responses - Kenji Kabashima (Japan)

3. IL-4Rα Blockade Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis - Chris Callewaert (Belgium)

4. Autoinflammation and autoimmunity in psoriasis vs hidradenitis suppurativa - Antonio Martorell (Spain)

 

FREE COMMUNICATIONS:
 

P007

THE ROLE OF NEUROIMMUNE INTERACTION IN PATHOPHYSIOLOGY OF GRANULOMATOUS ROSACEA

E.Hong *, K.Kim  (Gyeonggi-do, Korea, Republic Of)

 

P008

ROLE OF KERATIN 24 IN HUMAN EPIDERMAL KERATINOCYTES

M.Zheng *, M.Min , X.Man  (Hangzhou, China)

 

 

08.30-10.00 – Focus Session 4: Beyond the skin

 

Chairs: Paolo Gisondi (Italy)

 

1. Psychological and psychiatric comorbidities in major inflammatory skin diseases - Marta Garcia-Bustinduy (Spain)

2. Hepatic and musculoskeletal disease in psoriasis - Paolo Gisondi (Italy)

3. Cardiovascular comorbidities in major inflammatory skin diseases - Stefano Piaserico (Italy)

 

 
FREE COMMUNICATIONS:
 

P009

THERAPEUTIC PATIENT EDUCATION AND SELF-MANAGEMENT SUPPORT FOR PATIENTS WITH PSORIASIS – A LIVING SYSTEMATIC REVIEW AND META-ANALYSIS

C.Dressler , M.Zidane , L.Grine , P.Galdas , J.Lambert , A.Nast * (Berlin, Germany)

 

P010

DEVELOPMENT OF A PATIENT CHARTER FOR PEOPLE LIVING WITH CONDITIONS, DISEASES OR TRAUMAS INVOLVING THE SKIN

A.Sivanand , K.Andrews-Clay * (Ottawa, Canada)

 

 

10.30-12.30 – Plenary 2: Novelties in therapeutics

 

Chairs: Pablo de la Cueva (Spain) & Thomas Luger (Germany)

 

1. Anti TNF and small molecules in psoriasis - Sandra Philipp (Germany)

2. Anti IL17 in psoriasis - Carle Paul (France)

3. Anti p40/anti p19 in psoriasis - Kristian Reich (Germany)

4. New molecules in atopic dermatitis - Diamant Thaçi (Germany)

5. Which drug for which patient ? - Emilie Sbidian (France)

6. Latest trials on the effect of biotherapy on cardiovascular disease in psoriasis - Nehal Mehta (US)

 

12.30-14.00    Lunch break / Satellite Symposia

 

14.00-15.30    Focus Session 5 - Topical treatments and physical modalities of treatment

 

Chairs: José Manuel Carrascosa (Spain) & Lajos Kemeny (Hungary)

 

1. Topical therapy in psoriasis and atopic dermatitis - José Manuel Carrascosa (Spain)

2. UVB in psoriasis and atopic dermatitis - Piergiacomo Calzavara (Italy)

3. Innovative phototherapeutic approaches in psoriasis and atopic dermatitis - Lajos Kemeny (Hungary)

4. Physical treatment modalities in hidradenitis suppurativa - Speaker TBC

 

 
14.00-15.30 – Focus Session 6 – Advances and latest insights in non biologic systemic therapeutic agents in psoriasis and atopic dermatitis
 

Chairs: Raquel Rivera (Spain) & Martine Bagot (France)

 

1. Fumarates / Vitamin A Derivatives  - Peter van de Kerkhof (Netherlands)

2. CsA / MMF /Azathioprine - César Gonzalez (Colombia)

3. MTX - Rolland Gyulai (Hungary)

4. Apremilast and -inibs - Richard Langley (Canada)

 

FREE COMMUNICATIONS:
 

P011

UPADACITINIB IMPROVED PATIENT-REPORTED PRURITUS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL

C.-H.Hong *, T.Wu , B.Calimlim , H.Teixeira , M.de Bruin-Weller  (Surrey, Canada)

 

P012

DRUG SURVIVAL OF FUMARIC ACID ESTERS (FAE) FOR MODERATE-TO-SEVERE PSORIASIS IN A GERMAN PSORIASIS REGISTRY: PSOBEST

K.Reich , M. A.Radtke , C.Sorbe *, M.Augustin  (Hamburg, Germany)

 

P013

INTERIM ANALYSIS OF SKILL NON-INTERVENTIONAL STUDY: DIMETHYLFUMARATE IN LONG-TERM TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ROUTINE PRACTICE – CHARACTERISATION OF PATIENT POPULATION IN COMPARISON WITH PSOBEST AND PSOHEALTH

M.Augustin , C.Sorbe *, A.Kirsch , S.Diemert  (Hamburg, Germany)

 

 

15.30-18.00: SPIN Forum

 

Chairs: Louis Dubertret (France) & Chih-ho Hong (Canada)

 

1. Limitations on access to conventional/biologic therapy around the world - Maria Lorna Frez (Philippines), Nejib Doss (Tunisia), 
2. Screening and follow up for conventional/biologic therapy - Carlos Muñoz (Spain), Emad Elgamal (Egypt)

3. Infections in patients under immunosuppressive drugs: learning from difference - Marta Ferran (Spain), Fernando Valenzuela (Chile), Ibrahim Almukahal (Libya)


Discussion

 

15.30-18.00:  How do I manage?
 

Chairs: Luis Puig (Spain), Peter Van de Kerkhof (Netherlands) & AJ Kanwar (India)

 

1. Pregnancy - Juan Raul Castro (Colombia)

2. Childhood psoriasis - Marieke Seyger (Netherlands)

3. Chronic hepatic disease - Eva Vilarassa (Spain)

4. Chronic infections - Fatimata Ly (Senegal)

5. Nail psoriasis - Bertrand Richert (Belgium)

6. Recalcitrant atopic dermatitis - Esther Serra (Spain)

 

 

Saturday, April 27

 

08.30-10.00 – Focus Session 7: Treatment goals/guidelines in major inflammatory skin diseases
 

Chair: Luis Puig (Spain)

 

1. Treatment goals in psoriasis - Ulrich Mrowietz (Germany)

2. Guideline variability across countries - Jashin Wu (US)

3. Drug survival - Elke de Jong (Netherlands)

4. Treatment outcomes and goals in atopic dermatitis - Esther Serra (Spain)

 

 

08.30-10.00 – Focus Session 8: Individualized therapy in major inflammatory skin diseases

 

Chairs: Jan Gutermuth (Belgium) & Ronald Vender (Canada)

 

1. Treat to target - Alexander Nast (Germany)

2. Transitioning between biologics - Ronald Vender (Canada)

3. Combination therapy - Pablo Coto (Spain)

4. Therapeutic drug monitoring in biologics - Ann Gils (Belgium)

 

FREE COMMUNICATIONS:
 

P014

IDENTIFICATION OF CLINICAL AND BIOMARKER PARAMETERS ASSOCIATED WITH LONG-TERM MAINTENANCE OF PASI 90 RESPONSE FOLLOWING GUSELKUMAB TREATMENT WITHDRAWAL IN PSORIASIS

X.Liu , P.Branigan , Y.Chen , B.Scott , M.Banaszewska , P.McGovern , Z.Yao , S. Fakharzadeh *, S.Li , Y.Wasfi , M.Song , K.Campbell  , E. J.Muñoz-Elías   (Spring House, United States)

 

P015

DEFINING A MINIMAL EFFECTIVE SERUM TROUGH CONCENTRATION OF SECUKINUMAB IN PSORIASIS: A STEP TOWARDS PERSONALIZED THERAPY

R.Soenen , E.Meulewaeter , L.Grine , N.Van den Berghe , B.Els , R.Speeckaert , S.Lanssens , L.Temmerman , J.Lambert *, A.Gils  (Ghent, Belgium)

 

 

10.30-12.30 – Plenary 3: Outcomes in psoriasis

 

Chairs: Jo Lambert (Belgium) & Ulrich Mrowietz (Germany)

 

1. Intro to value based healthcare, applied to a chronic disease model - Jan Gutermuth (Belgium)

2. Patient relevant outcome measures in psoriasis (IDEOM) - Alice Gottlieb (US)

3. Measures to treat psoriasis beyond drugs - Ulrich Mrowietz (Germany)

4. Can we justify the cost of a value based psoriasis approach? - Matthias Augustin (Germany)

 

12.30-14.00    Lunch break / Satellite Symposia

 

14.00-15.30 – Focus Session 9: Empowering HCPs in leadership and management

 

Chair: Jo Lambert (Belgium)

 

1. How to use resources effectively? - Jo Lambert (Belgium)

2. How to organise multidisciplinary teams? - Speaker TBC

3. How to deal with non-adherence in patients? - Rachael Thorneloe (UK)

4. Shared decision making in chronic illnesses - Phyllis Spuls (Netherlands)

 

FREE COMMUNICATIONS:
 

P016

PLAQUE PSORIASIS IN HARD-TO-TREAT BODY LOCATIONS: CLINICAL MANAGEMENT AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS TREATED WITH BIOLOGIC AGENTS

W.Gulliver *, S.Gulliver , M.DiBattista , A.Kavanagh , S.Randell , R.Power , N.Gladney , H.Wang , D.MacDonald , S.Montmayeur , R.Burge  (St. John's, Canada)

 

 

 

14.00-15.30 – Focus Session 10: Special situations: children, pregnancy, old age, cancer patients in major inflammatory skin diseases

 

Chairs: Isabel Belinchon (Spain)

 

1. Pediatric patients with severe major inflammatory skin diseases - Speaker TBC

2. Paradoxical reactions - Anna Lopez (Spain)

3. Scalp and genital psoriasis - Maria Lorna Frez  (Philippines)

4. Old age/cancer patients - Satish Lubeek (Netherlands)

 

FREE COMMUNICATIONS:
 

P017

CO-EXISTENCE OF PSORIASIS AND ATOPIC DERMATITIS IN SAME PATIENTS AND FAMILIES

R.konathan *, B. S.papisetty , S. K.alur  (Hyderabad, India)

 

 

 

16.00-17.45 - Plenary 4: Medical need and Challenges in other Inflammatory Dermatoses
 
Chairs: Jo Lambert (Belgium) & Thomas Luger (Germany)
 
1. State of the art and future challenges in vitiligo - Nanja van Geel (Belgium)
2. State of the art and future challenges in alopecia areata - Speaker TBC
3. State of the art and future challenges in hidradenitis suppurativa - Errol Prens (Netherlands)

 

17.45-18.00 Closing remarks 
 

 

By continuing to browse this website, you accept cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Ok Read more